Skip to main content
Category

Participants

MIND Matters | Quarterly Newsletter | Winter 2023

By Clinical Trials, Commentary, Community Events, COVID-19, In the News, Longitudinal Cohort, Participants, UCI MIND

Message from the Director Dear Friends of UCI MIND, Advances in the field of Alzheimer’s disease (AD) research and the contributions of UCI MIND investigators remain tremendously exciting. Two new drugs have been approved by the FDA (page 3). These approvals are believed by many to represent the dawn of a new age in AD research and treatment. Both drugs received accelerated approval and we await a decision from the FDA about “full approval” for lecanemab. If received, full approval could cause the Centers for Medicare and Medicaid Services to revisit their previous coverage decision about anti-amyloid antibody therapies. These…

The post MIND Matters | Quarterly Newsletter | Winter 2023 appeared first on UCI MIND.

Read More

MIND Matters | Quarterly Newsletter | Fall 2022

By Clinical Trials, Commentary, Community Events, COVID-19, In the News, Longitudinal Cohort, Participants, UCI MIND

Message from the Director Dear Friends of UCI MIND, As the fall MIND Matters newsletter goes to print, many of us are preparing to travel to San Francisco for the annual Clinical Trials in Alzheimer’s Disease (CTAD) meeting, where we will hear important results from recently completed Phase 3 clinical trials of potential new therapies for Alzheimer’s disease (AD). This includes trials of lecanemab (page 1) as well as other treatments. The topline results for lecanemab announced by the trial sponsors are exciting and suggest that lecanemab may slow the progression of AD. The availability of treatments to slow the…

The post MIND Matters | Quarterly Newsletter | Fall 2022 appeared first on UCI MIND.

Read More

MIND Matters | Quarterly Newsletter | Summer 2022

By Clinical Trials, Commentary, Community Events, COVID-19, In the News, Longitudinal Cohort, Participants, UCI MIND

Message from the Director Dear Friends of UCI MIND, We hope that you had a summer full of sun, fun, and good health. As you can see in this issue of MIND Matters, it has been a busy summer here at UCI MIND. Our investigators played a prominent role at the annual Alzheimer’s Association International Conference (AAIC), a focus of this issue (p 1, 3, 6, and 7). We’re very proud of our own Maria Corrada, ScD, who played a role in planning this important meeting (p 1 and 7), as well as the many researchers who presented their work….

The post MIND Matters | Quarterly Newsletter | Summer 2022 appeared first on UCI MIND.

Read More

Laguna Woods resident endured horrors of Holocaust and got a fresh start in the U.S.

By Carousel Slider, In the News, Participants, UCI MIND

When [Helen] Weil was in her 90s, she enrolled in the 90+ Study, a UC Irvine program initiated in 2003 to study “the oldest-old.” The program started in 1981 as the Leisure World Cohort Study, in which Leisure World residents in their 90s filled out surveys about what contributed to their longevity. … UCI researchers visit participants every six months to chart their physical health and memory functions. … Weil’s age group, 90 and above, was featured in CBS’ “60 Minutes” with Leslie Stahl, first in 2014 and again in 2020. Learn more about The 90+ Study here > Read…

The post Laguna Woods resident endured horrors of Holocaust and got a fresh start in the U.S. appeared first on UCI MIND.

Read More

Testing effective treatments as potential preventions

By Commentary, In the News, Participants, UCI MIND

Contributed by Joshua Grill, PhD Since Wednesday’s announcement by Eisai and Biogen of positive topline Phase 3 results for their treatment lecanemab in early Alzheimer’s disease, the field has been markedly aligned. Most agree that we need to see the data but that this seems to be a clear win and an important step in a positive direction. Some debates have begun, and more will happen, about the size and meaning of the win—that is, the size of the drug’s disease-slowing effects and the clinical meaningfulness. These debates will be extremely important but will take time. Combined with recently published…

The post Testing effective treatments as potential preventions appeared first on UCI MIND.

Read More

MIND Matters | Quarterly Newsletter | Spring 2022

By Clinical Trials, Commentary, Community Events, COVID-19, In the News, Longitudinal Cohort, Participants, UCI MIND

Message from the Director Dear Friends of UCI MIND, Welcome to the new normal. COVID case numbers have surged again, but our research continues to push forward and our researchers have enthusiastically resumed in-person activities that have been few and far between over the last two years. This includes attending and holding scientific conferences, generally through hybrid formats, allowing those comfortable and ready to reconvene in-person to present new data, exchange ideas and forge new collaborations. Some UCI MIND investigators recently traveled to Barcelona, Spain to attend the International Conference on Alzheimer’s Disease and Parkinson’s Disease and related neurological disorders…

The post MIND Matters | Quarterly Newsletter | Spring 2022 appeared first on UCI MIND.

Read More

MIND Matters | Quarterly Newsletter | Winter 2022

By Clinical Trials, Commentary, Community Events, COVID-19, In the News, Longitudinal Cohort, Participants, UCI MIND

Message from the Director Dear Friends of UCI MIND, The COVID-19 surge caused by the Omicron variant has produced unwanted challenges for our research. Yet, our investigators remain unrelenting and highly successful in their work. Dr. Ira Lott received the international Trisomy 21 Research Society Montserrat Trueta Award (page 1). Dr. Claudia Kawas received the UCI Senate Better World Award (page 5). We honored Bob and Virginia Naeve with our UCI MIND Award, though we were unable to hold our A December to Remember Gala, to deliver it with the pomp and circumstance they deserve (page 7). Cherry Justice has…

The post MIND Matters | Quarterly Newsletter | Winter 2022 appeared first on UCI MIND.

Read More

Celebrating Black Americans’ contributions to Alzheimer’s research

By Commentary, In the News, Participants, UCI MIND

Contributed by Christian Salazar, PhD Black Americans are more likely than White Americans to be afflicted with Alzheimer’s disease. This may be of no surprise considering that some of the same risk factors of heart disease that disproportionately affect African Americans in midlife- obesity, type-2 diabetes, hypercholesterolemia, hypertension- can also impact brain health later in life. Black Americans can therefore benefit from participating in clinical trials like the AHEAD 3/45 study, which aims to test whether an investigational treatment can slow or stop the earliest brain changes due to Alzheimer’s disease in people with a higher risk of developing the…

The post Celebrating Black Americans’ contributions to Alzheimer’s research appeared first on UCI MIND.

Read More
English